Page 65 - Read Online

Gonzaga-Jauregui et al. Rare Dis Orphan Drugs J 2024;3:16 https://dx.doi.org/10.20517/rdodj.2024.02 Page 9 of 10

REFERENCES
1. Borrajo GJC. Newborn screening in Latin America: a brief overview of the state of the art. Am J Med Genet C Semin Med Genet
2021;187:322-8. DOI
2. Giugliani R, Castillo Taucher S, Hafez S, et al. Opportunities and challenges for newborn screening and early diagnosis of rare
diseases in Latin America. Front Genet 2022;13:1053559. DOI PubMed PMC
3. American College of Medical Genetics/American Society of Human Genetics Test and Technology Transfer Committee
Working Group. Tandem mass spectrometry in newborn screening. American college of medical genetics/American society of
human genetics test and technology transfer committee working group. Genet Med 2000;2:267-9. DOI PubMed
4. Vela-Amieva M, Belmont-Martínez L, Ibarra-González I, Fernández-Lainez C. Institutional variability of neonatal screening in
Mexico. Bol Med Hosp Infant Mex 2009;66:431-9. Available from: https://www.medigraphic.com/cgi-bin/new/resumenI.
cgi?IDARTICULO=21973 [Last accessed on 14 Jun 2024].
5. García-Flores EP, Herrera-Maldonado N, Hinojosa-Trejo MA, Vergara-Vázquez M, Halley-Castillo ME. Progress and achievements
of the neonatal metabolic screening program (2012-2018). Pediatr Act Mex 2018;39:57. DOI
6. Camino HC, Cantú-Reyna C. Incidencia de errores innatos del metabolismo, endocrinopatías, hemoglobinopatías y otros desórdenes
detectados por tamiz metabó lico ampliado. Rev Médica Petróleos Mex 2018;11:72-83. Available from: https://www.researchgate.
net/publication/339565795_Incidencia_de_errores_innatos_del_metabolismo_endocrinopatias__otros_desordenes_detectados_por
_tamiz_ metabolico_ampliado [Last accessed on 20 Jun 2024].
7. Navarrete-Martínez JI, Limón-Rojas AE, Gaytán-García MJ, et al. Newborn screening for six lysosomal storage disorders in a cohort
of Mexican patients: three-year findings from a screening program in a closed Mexican health system. Mol Genet Metab 2017;121:16-
21. DOI
8. Trigo-Madrid M, Díaz-Gallardo J, Mar-Aldana R, et al. Results of the expanded neonatal screening program and perinatal
epidemiology in the health services of the secretariat of the navy of Mexico. Pediatr Act Mex 2014;35:448-58. Available from: http://
www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0186-23912014000600003&lng=es&tlng= [Last accessed on 14 Jun 2024].
9. XVI legislature of the state of Quintana Roo, decree to reform article 56 of the state health law. Available from: http://documentos.
congresoqroo.gob.mx/decretos/EXVI-2021-09-04-137.pdf [Last accessed on 14 Jun 2024].
10. LXV legislature of the state of Quintana Roo. Available from: https://congreso-gto.s3.amazonaws.com/uploads/orden_archivo/archivo/
31179/14_Dictamen_refLSE_materinf-tamizmeapli_240-323B-413-LXV-I.pdf [Last accessed on 14 Jun 2024].
11. LXV legislature of the congress of the United Mexican States. Decree to reform article 157 bis of the general health law. Available
from: https://www.diputados.gob.mx/LeyesBiblio/minutas/65/CS-LXV-I-1P-022/02_dictamen_a2_010_08mar23.pdf [Last accessed
on 14 Jun 2024].
12. Lazcano-Ponce E, Schiavon R, Uribe-Zúñiga P, et al. Coverage for birth care in Mexico and its interpretation within the context of
maternal mortality. Publ Health Mex 2013;55:S214-24. DOI
13. Ibarra-González I, Fernández-Lainez C, Vela-Amieva M, et al. A review of disparities and unmet newborn screening needs over 33
years in a cohort of Mexican patients with inborn errors of intermediary metabolism. Int J Neonatal Screen 2023;9:59. DOI PubMed
PMC
14. Chaytow H, Faller KME, Huang YT, Gillingwater TH. Spinal muscular atrophy: from approved therapies to future therapeutic targets
for personalized medicine. Cell Rep Med 2021;2:100346. DOI PubMed PMC
15. NeuroVoices: Crystal Proud, MD, on improving SMA outcomes through a combination approach. Available from: https://
www.neurologylive.com/view/neurovoices-crystal-proud-improving-sma-outcomes-through-combination-approach [Last accessed on
20 Jun 2024].
16. Bodian DL, Klein E, Iyer RK, et al. Utility of whole-genome sequencing for detection of newborn screening disorders in a population
cohort of 1,696 neonates. Genet Med 2016;18:221-30. DOI
17. Ceyhan-Birsoy O, Murry JB, Machini K, et al. Interpretation of genomic sequencing results in healthy and ill newborns: results from
the BabySeq project. Am J Hum Genet 2019;104:76-93. DOI
18. Velásquez A, Vela-Amieva M, Waylor EW, Chace DH. Results of the sieve enlarged newborn, as new strategy for the prevention of
the defects from birth. Rev Mex Pediatr 2000;67:206-13. Available from https://www.medigraphic.com/cgi-bin/new/resumen.
cgi?IDARTICULO=2748 [Last accessed on 14 Jun 2024].
19. Downie L, Halliday J, Lewis S, Amor DJ. Principles of genomic newborn screening programs: a systematic review. JAMA Netw Open
2021;4:e2114336. DOI PubMed PMC
20. Stark Z, Scott RH. Genomic newborn screening for rare diseases. Nat Rev Genet 2023;24:755-66. DOI PubMed
21. Minten T, Gold NB, Bick S, et al. Determining the characteristics of genetic disorders that predict inclusion in newborn genomic
sequencing programs. medRxiv 2024. DOI PubMed PMC
22. Bros-facer V, Taylor S, Patch C. Next-generation sequencing-based newborn screening initiatives in Europe: an overview. Rare Dis
Orphan Drugs J 2023;2:21. DOI
23. Florentine MM, Rouse SL, Stephans J, et al. Racial and ethnic disparities in diagnostic efficacy of comprehensive genetic testing for
sensorineural hearing loss. Hum Genet 2022;141:495-504. DOI PubMed PMC
24. Chen E, Facio FM, Aradhya KW, et al. Rates and classification of variants of uncertain significance in hereditary disease genetic
testing. JAMA Netw Open 2023;6:e2339571. DOI PubMed PMC